ERBB2 and breast cancer: In addition, bevacizumab is the only antiangiogenic drug approved by the FDA for the first-line management of NSCLC and HER2-negative breast cancer, and second-line treatment of glioblastoma, and metastatic renal cell carcinoma [87].